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Capsule summary 
The pathophysiology of the severe complications of COVID-19 is still unclear. We report preliminary data 
providing evidence of complement activation in patients with COVID-19 with different degrees of 
respiratory failure. 
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To the Editor: 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the coronavirus responsible for the 
current pandemic of coronavirus disease 2019 (COVID-19), whose very broad clinical spectrum ranges from 
minor signs and symptoms such as cough and mild fever to severe pneumonia with dyspnea, tachypnea, and 
impaired gas exchange, leading to severe and life-threatening manifestations in approximately 15% of 
infected patients1. Increased levels of pro-inflammatory cytokines and coagulation activation markers2 
indicate that a sustained inflammatory response to viral infection and the related prothrombotic state are 
involved in the development of these clinical manifestations. Such a picture is reminiscent of comparable 
manifestations in various autoimmune/inflammatory disorders characterised by a prothrombotic state and 
endothelial perturbation triggered by systemic inflammation or macrophage activation 2 and 
microangiopathies that complicate solid organ and bone marrow transplantations 3. 
The complement system is a key mediator of the innate immune response that protects against 
infectious agents such as viruses 4 but, in addition to being an important part of the immuno-defence system, 
it also plays a critical role in promoting the inflammatory process that leads to tissue injury. Furthermore, it 
has long been recognized that a crosstalk between complement and the coagulation system exists 3. The 
activation peptide of complement component 5 (C5a) and the membrane attack complex (MAC/C5b-9) drive 
neutrophil activation and the inflammation that eventually leads to endothelial damage 3. However, although 
the role of complement in the acute respiratory distress syndrome (ARDS) caused by influenza, respiratory 
syncytial and the previous SARS-CoV viruses is well established 4, its contribution to COVID-19 is still 
unclear. Diao et al. have found that acute renal failure associated with tubular necrosis and abundant 
complement deposition develops in a significant percentage of patients with severe COVID-19, which 
suggests that complement plays a pathogenic role 5, and Gao et al. have reported in a preprint increased 
serum levels of C5a in a small series of patients with severe COVID-19 6. 
We investigated the plasma levels of sC5b-9 and C5a as markers of complement activation in 31 COVID-19 
patients: 21 men and 10 women with a median age of 59 years (range 31-85). The study was approved by the 
Ethics Committee of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan (No. 
360_2020) and was carried out in conformity with the 2013 revision of the Declaration of Helsinki. 
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Seventeen of these patients were admitted to our Respiratory Unit for intermediate care with continuous 
positive airway pressure (CPAP) and were considered as having moderate COVID-19; the remaining 14 
were admitted to our intensive care unit (ICU) for mechanical ventilation and were considered as having 
severe disease 2. All of the patients received subcutaneous low-molecular-weight heparin at a twice daily 
dose of 100 IU/kg and oral hydroxychloquine at a twice daily dose of 200 mg. EDTA plasma samples were 
obtained from a single venipuncture performed 1 to 6 days after the admission, immediately frozen, and 
stored at -80C° before testing. The levels of soluble C5b-9 (sC5b-9) were measured by means of solid-phase 
assays (MicroVue Complement SC5b-9 Plus EIA kit, Quidel Corporation, San Diego, CA, USA) with intra- 
and inter-assay coefficients of variation (CVs) of respectively 6.8% and 13.1%, and plasma C5a levels were 
measured using an immunoenzymatic method (MicroVue Complement C5a EIA, Quidel Corporation) with 
intra- and inter-assay CVs of <12%.  
The controls for the complement assays were 27 healthy subjects: 19 men and eight women with a median 
age of 55 years (range 34-78). 
The following laboratory parameters were collected from the patients’ clinical records: fibrin fragment D-
dimer, C-reactive protein (CRP), interleukin-6 (IL-6), ferritin, white blood cells, neutrophils, lymphocytes, 
platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen. The data are 
given as median values and ranges (minimum–maximum). The between-group differences were analysed 
using the MannWhitney test for independent samples, and the correlations between the different 
parameters were evaluated using Spearman’s test. A P value of <0.05 was considered significant. 
Figure 1 shows the levels of sC5b-9 and C5a in the two groups of patients and the normal controls. The 
plasma levels of sC5b-9 (upper panel) were significantly higher in the patients with moderate disease 
(median 556 ng/mL, range 253-1223) and those with severe disease (746 ng/mL, range 465-1555) than in the 
healthy controls (217 ng/mL, range 106-499) (P=0.0001 for both), and significantly higher in the patients 
with severe disease than in those with moderate disease (P=0.015). The plasma levels of C5a (lower panel) 
were higher in the patients with moderate disease (16.99 ng/mL, range 9.24-22.99) and those with severe 
disease (15.55 ng/mL, range 10.9-21.89) than in the healthy controls (7.28 ng/mL, range 3.47-11.83) 
(P=0.0001 for both), with no statistically significant difference between the two patient groups.  
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It is worth noting that the levels of sC5b-9 were surprisingly high in a few patients whose C5a levels fell 
within the normal range. This can be explained by the fact that C5a is cleared more rapidly than sC5b-9 and 
suggests that sC5b-9 may be a more reliable marker of in vivo complement activation.   
Table 1 shows the analysed coagulation and inflammation parameters in the two patient groups. In line with 
recent findings 1,2, our cohort of COVID-19 patients had increased levels of acute-phase proteins and 
coagulation system abnormalities. Although there is a slight correlation between the plasma levels of sC5b-9 
and C5a and CRP levels (r=0.439, P= 0.013 and r=0.449, P=0.011), the activation products of the 
complement cascade seem to behave as independent variables, thus raising the question as to whether 
measuring complement activation products is more sensitive and predictive of disease outcome. Future 
prospective studies also including patients with mild COVID-19 should be carried out to investigate this 
hypothesis. We are now conducting such a study to assess the trend of complement activation markers from 
the admission through hospitalization to complete remission. The increased C5a levels observed in our 
COVID-19 patients are consistent with the well-established role of C5a in promoting the lung sequestration 
of leukocytes and pulmonary dysfunction, and it has also been shown that sC5b-9 has similar effects by 
causing transendothelial leukocyte migration and vascular leakage 4. Overall, these findings suggest that 
complement activation may contribute to the development of lung and endothelial damage in patients with 
COVID-19. However, consideration should also be given to the possibility that the coronavirus may directly 
cause damage to endothelial cells. Indeed, in a post-mortem study performed in 3 patients, electron 
microscopy revealed viral inclusion structures in endothelial cells and histological analyses showed an 
accumulation of inflammatory cells associated with endothelium 7. A number of research laboratories are 
making a major effort to develop therapeutic strategies for controlling COVID-19 infection. In addition to 
looking for drugs that prevent viral entry into target cells and virus replication, they are also seeking 
satisfactory treatments for the serious clinical manifestations often associated with the disease, including the 
severe interstitial pneumonia, sepsis, heart failure and excessive blood clotting that can lead to a fatal 
outcome. One of the aims of the currently investigated therapeutic strategies is to induce a marked reduction 
in the inflammatory response to viral infection documented by increased levels of pro-inflammatory 
cytokines. Our data show that complement activation is frequent in patients with COVID-19 patients and 
probably involved in the pathophysiology of its clinical complications. Complement may act in combination 
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with and possibly upstream of other mediators, thus suggesting the possibility that complement blocking 
drugs may be a beneficial addition to the therapeutic armamentarium against COVID-19. In particular, the 
block of complement may be obtained by specific drugs targeting C5 or the mannan-binding lectin-
associated serine protease-2 (MASP-2) by the humanized monoclonal antibody eculizumab or the human 
monoclonal antibody narsoplimab, respectively 8. Moreover, intravenous immunoglobulins may hamper 
complement cascade amplification decreasing C5 activation and deposition of the membrane attack complex 
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FIGURE LEGEND 
Figure 1. Plasma levels of complement terminal complex sC5b9 (upper panel) and activated complement 
component 5 (C5a) (lower panel) in 17 COVID-19 patients requiring continuous positive airway pressure 
(moderate) and 14 COVID-19 patients requiring mechanical ventilation (severe). The horizontal lines 
represent median values.
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Table 1. Coagulation and inflammation parameters expressed as median values and ranges in 17 COVID-19 patients requiring continuous positive airway 
pressure (moderate) and 14 COVID-19 patients requiring mechanical ventilation (severe). 
 
 D-dimer 
μg/L 
CRP 
mg/dL 
Ferritin 
μg/L 
IL-6 
ng/L 
White cells 
n/μL 
Neutrophils 
n/μL 
Lymphocytes 
n/μL 
Platelets 
n x 103/μL 
PT 
ratio 
aPTT 
ratio 
Fibrinogen 
mg/dL 
Moderate 1275 3.41 1122 20.1 8060 6600 1000 342 1.17 0.91 472 
 
290-21639 0.55-18.24 69-8633 1.5-268.0 2830-172910 1560-12510 380-3330 70-799 0.96-5.43 0.71-1.21 229-819 
 
           
Severe 1565 9.00 1269 33.3 9190 8005 650 322 1.11 0.92 499 
 
471-19548 1.61-34.15 216-5064 3.8-300.0 2310-51410 1300-49680 200-1650 72-608 1.02.1.35 0.81-1.15 228-1035 
 
           
Normal 
ranges 
<500 0.00-0.05 30-400 <10 4800-10800 1500-6500 1200-3400 130-430 0.84-1.20 0.86-1.20 165-350 
 

